Biopharma Leaders Fireside Chat: Clinical Reflections on the Past Year & Positioning In Vivo Cell & Gene Therapies in Pharma Portfolios
9:00 am - Wednesday 29th July 2026
- Distilling the past year’s clinical and translational progress into portfolio-relevant proof points, sharpening investment, and resource allocation
- Prioritizing indications and modalities where in vivo approaches add differentiated value alongside existing assets, focusing pipeline sequencing
- Aligning global development routes, data portability, and CMC readiness with near-term regulatory and commercial realities, accelerating time to value
